SPOTLIGHT -
March 7th 2024
The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.
January 29th 2024
Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.
October 9th 2023
The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.
October 2nd 2023
Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.
August 9th 2023
Feelings of depression and stress are partly to blame for lower fitness levels among people with rheumatoid arthritis.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More